Q1 Earnings Estimate for CVKD Issued By Zacks Small Cap

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at Zacks Small Cap issued their Q1 2025 earnings estimates for Cadrenal Therapeutics in a report released on Monday, March 31st. Zacks Small Cap analyst D. Bautz expects that the company will post earnings per share of ($1.13) for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q2 2025 earnings at ($1.24) EPS, Q3 2025 earnings at ($1.43) EPS, Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($5.30) EPS and FY2027 earnings at ($1.57) EPS.

Cadrenal Therapeutics Trading Down 1.0 %

Shares of NASDAQ CVKD opened at $17.46 on Wednesday. The stock has a fifty day moving average price of $18.80 and a 200 day moving average price of $16.05. The company has a market cap of $32.82 million, a P/E ratio of -2.61 and a beta of 1.40. Cadrenal Therapeutics has a 12-month low of $5.40 and a 12-month high of $22.90.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its earnings results on Thursday, March 13th. The company reported ($2.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.71) by ($1.03).

Institutional Investors Weigh In On Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Geode Capital Management LLC acquired a new stake in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned approximately 0.59% of Cadrenal Therapeutics as of its most recent SEC filing. 7.92% of the stock is currently owned by institutional investors.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.